SPRB
NASDAQSpruce Biosciences Inc.
Price$55.20+0.71 (+1.29%)
01:45 PM07:45 PM
News · 26 weeks59-30%
2025-10-262026-04-19
Mix2890d
- Other11(39%)
- SEC Filings11(39%)
- Leadership2(7%)
- Insider2(7%)
- Offering2(7%)
Latest news
25 items- SECSpruce Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSEC Form 424B5 filed by Spruce Biosciences Inc.424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsSpruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the pricing of its previously announced underwritten public offering of 1,150,000 shares of its common stock at a price to the public of $50.00 per share and, in lieu of shares of common stock to a certain investor, pre-funded warrants to purchase 50,000 shares of common stock at a purchase price of $49.99 per share, which equals the public offering price per share of the common stock less the $0.01 exercise price per share of each pre-funded warrant. T
- SECSEC Form 424B5 filed by Spruce Biosciences Inc.424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsSpruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce Biosciences. In addition, Spruce Biosciences expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15% of the aggregate number of shares sold in the offering at the public offeri
- SECSEC Form DEFA14A filed by Spruce Biosciences Inc.DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSEC Form DEF 14A filed by Spruce Biosciences Inc.DEF 14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Hooks Corwin Dale4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hooks Corwin Dale3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- SECSEC Form 424B5 filed by Spruce Biosciences Inc.424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSEC Form S-8 filed by Spruce Biosciences Inc.S-8 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSEC Form 10-K filed by Spruce Biosciences Inc.10-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesFollowing Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update
- PRSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible
- PRSpruce Biosciences to Present at Upcoming Investor Conferences in MarchSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March. Leerink Global Healthcare Conference Date and Time: March 9, 2026, at 11:20 a.m. ET Format: Fireside chat and 1x1 meetings Location: Miami, FL The Citizens Life Sciences Conference Date and Time: March 10, 2026, at 12:30 p.m. ET Format: Fireside chat and 1x1 meetings Location: Miami, FL Interested parties can access the live webcasts
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Spruce Biosciences Inc.SCHEDULE 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- PRSpruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming biologics license application (BLA) submission for tralesinidase alf
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- PRSpruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 3:20 p.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the Company's website for approximately 90 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)